首页> 美国卫生研究院文献>Journal of Clinical Microbiology >High-Resolution Melting Approach to Efficient Identification and Quantification of H275Y Mutant Influenza H1N1/2009 Virus in Mixed-Virus-Population Samples
【2h】

High-Resolution Melting Approach to Efficient Identification and Quantification of H275Y Mutant Influenza H1N1/2009 Virus in Mixed-Virus-Population Samples

机译:高效融解方法可有效鉴定和定量混合人群中的H275Y突变型H1N1 / 2009病毒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The single-nucleotide variation 823C to T (His275Tyr), responsible for oseltamivir drug resistance has been detected in some isolates of the influenza A/H1N1/2009 virus. Early detection of the presence of this oseltamivir-resistant strain allows prompt consideration of alternative treatment options. An isolated-probe–asymmetric amplification PCR (Roche LightCycler v2.0) and high-resolution melting (HRM) method using unlabeled probes and amplified products (Idaho LightScanner 32) was designed and optimized to detect and estimate the proportion of H275Y mutants in influenza A/H1N1/2009 virus samples. The lower limit of quantification within the linear range of PCR assay detection was 200 copies/reaction. The melting peaks of the H275Y-specific unlabeled probe for the wild-type A/H1N1/2009 and H275Y mutant viruses were clearly distinguishable at 65.5°C and 69.0°C, respectively, at various ratios of wild-type/mutant virus population standards. The 95% detection limit for the 10% mutant sample pool was 1,200 copies/reaction (95% confidence interval, 669.7 to 3,032.6 copies/reaction). This HRM assay was tested with 116 archived clinical specimens. The quantitative HRM results obtained with samples containing mixed mutant–wild-type virus populations, at threshold cycle (CT) values of <29, compared well to those obtained with a pyrosequencing method performed by an independent laboratory. The quantitative feature of this assay allows the proportions of mutant and wild-type viral populations to be determined, which may assist in the conventional clinical management of infected patients and potentially more preemptive clinical management. This validated quantitative HRM method, with its low running cost, is well positioned as a rapid, high-throughput screening tool for oseltamivir resistance mutations in influenza A/H1N1/2009 virus-infected patients, with the potential to be adapted to other influenza virus species.
机译:在A / H1N1 / 2009流感病毒的某些分离株中检测到负责oseltamivir耐药的单核苷酸变体823C至T(His275Tyr)。及早发现这种耐奥司他韦的菌株可以迅速考虑其他治疗方案。设计并优化了分离探针-不对称扩增PCR(Roche LightCycler v2.0)和使用未标记探针和扩增产物(Idaho LightScanner 32)的高分辨率解链(HRM)方法,以检测和评估流感病毒中H275Y突变体的比例A / H1N1 / 2009病毒样本。 PCR分析检测的线性范围内的定量下限为200拷贝/反应。野生型A / H1N1 / 2009和H275Y突变型病毒的H275Y特异性未标记探针的熔解峰在不同比例的野生型/突变型病毒种群标准下分别在65.5°C和69.0°C时清晰可见。 10%突变样品池的95%检测极限为1,200拷贝/反应(95%置信区间,669.7至3,032.6拷贝/反应)。使用116个存档的临床标本对HRM分析进行了测试。使用阈值循环(CT)值小于29的混合突变野生型病毒种群样品获得的定量HRM结果与独立实验室采用焦磷酸测序方法获得的结果相比较。该测定的定量特征允许确定突变型和野生型病毒种群的比例,这可以有助于感染患者的常规临床管理以及潜在的更先发性的临床管理。这种经过验证的定量HRM方法具有较低的运行成本,非常适合作为A / H1N1 / 2009流感病毒感染患者对奥司他韦耐药性突变的快速,高通量筛选工具,并有可能适应其他流感病毒种类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号